In 2023, Japan led global systemic hormonal preparation sales, valued at $2.58 billion, with a remarkable year-on-year growth of 12.9%. Germany followed at $1.56 billion, observing moderate growth of 2.23%. Canada, Spain, and Croatia also demonstrated growth, while Greece and Sweden experienced declines. The market in Japan and Costa Rica showed significant upward trends, in contrast to diminishing sales in Greece, Denmark, and Hungary. Observing a 5-year outlook, a compound annual growth rate will indicate varying paces of market dynamics across countries, with Japan poised for continued strength.
Future trends to watch include technological advancements in drug delivery systems and increasing demand for personalized medicine. Japan and Germany's markets may expand further due to aging populations and healthcare innovations. It's crucial to monitor regulatory changes and emerging markets, particularly in developing countries where healthcare access is improving.
Top countries in Systemic Hormonal Preparations Sales (Excluding Sex Hormones and Insulins) by Country
| # | 10 Countries | Million US Dollars | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Japan | 2,580 | 2023 | +1.62% | +12.9% | View data |
| 2 | 2 Germany | 1,560 | 2023 | +2.02% | +2.23% | View data |
| 3 | 3 Canada | 533.4 | 2023 | +1.99% | +4.27% | View data |
| 4 | 4 Spain | 466.6 | 2023 | +3.57% | +0.22% | View data |
| 5 | 5 Croatia | 148.7 | 2023 | +2.2% | +0.98% | View data |
| 6 | 6 Greece | 131.2 | 2023 | +0.85% | -3.53% | View data |
| 7 | 7 Sweden | 114.3 | 2023 | +4.19% | -1.84% | View data |
| 8 | 8 Czech Republic | 98 | 2023 | +2.73% | +1.16% | View data |
| 9 | 9 Switzerland | 94.8 | 2023 | +1.72% | +1.52% | View data |
| 10 | 10 Denmark | 73.1 | 2023 | -0.81% | -1.59% | View data |
